Study title: Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study - Bukstein DA, Bratton DI, Firriolo KM, Estojak J, Bird SR et al. 2003 (J Asthma 2003;40:475-85) Publication in CES clinical expert statement - Bruno Verdoncq - 28/08/07Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study - Bukstein DA, Bratton DI, Firriolo KM, Estojak J, Bird SR et al. 2003 (J Asthma 2003;40:475-85) Publication in CES clinical expert statement - Bruno Verdoncq - 28/08/07
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: CROMOGLICIC ACID | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: - | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |